应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
OMER 奥麦罗制药
休市中 05-03 16:00:00 EDT
3.73
+0.01
+0.27%
盘后
3.80
+0.07
+1.88%
18:56 EDT
最高
3.84
最低
3.61
成交量
15.88万
今开
3.76
昨收
3.72
日振幅
6.18%
总市值
2.16亿
流通市值
1.93亿
总股本
5,794万
成交额
58.85万
换手率
0.31%
流通股本
5,171万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Omeros Corp 预计每股亏损58美分 - 财报前瞻
Reuters · 05-03 19:41
Omeros Corp 预计每股亏损58美分 - 财报前瞻
奥麦罗制药盘中异动 股价大涨5.44%报3.59美元
自选股智能写手 · 05-02 22:33
奥麦罗制药盘中异动 股价大涨5.44%报3.59美元
奥麦罗制药盘中异动 股价大涨5.08%报3.31美元
自选股智能写手 · 05-02
奥麦罗制药盘中异动 股价大涨5.08%报3.31美元
奥麦罗制药盘中异动 早盘大幅拉升5.08%
自选股智能写手 · 04-29
奥麦罗制药盘中异动 早盘大幅拉升5.08%
奥麦罗制药盘中异动 快速拉升5.19%报3.24美元
自选股智能写手 · 04-23
奥麦罗制药盘中异动 快速拉升5.19%报3.24美元
奥麦罗制药盘中异动 股价大跌5.30%
自选股智能写手 · 04-20
奥麦罗制药盘中异动 股价大跌5.30%
奥麦罗制药盘中异动 股价大跌5.19%报3.57美元
自选股智能写手 · 04-16
奥麦罗制药盘中异动 股价大跌5.19%报3.57美元
奥麦罗制药盘中异动 快速跳水5.33%报3.73美元
自选股智能写手 · 04-13
奥麦罗制药盘中异动 快速跳水5.33%报3.73美元
奥麦罗制药盘中异动 急速拉升5.48%
自选股智能写手 · 04-12
奥麦罗制药盘中异动 急速拉升5.48%
奥麦罗制药盘中异动 下午盘股价大涨5.25%
自选股智能写手 · 04-11
奥麦罗制药盘中异动 下午盘股价大涨5.25%
奥麦罗制药盘中异动 早盘大幅拉升5.02%
自选股智能写手 · 04-09
奥麦罗制药盘中异动 早盘大幅拉升5.02%
奥麦罗制药盘中异动 早盘股价大涨6.71%报3.66美元
自选股智能写手 · 04-08
奥麦罗制药盘中异动 早盘股价大涨6.71%报3.66美元
奥麦罗制药盘中异动 早盘股价大涨5.13%
自选股智能写手 · 04-05
奥麦罗制药盘中异动 早盘股价大涨5.13%
奥麦罗制药盘中异动 早盘快速下跌13.79%
自选股智能写手 · 04-02
奥麦罗制药盘中异动 早盘快速下跌13.79%
奥麦罗制药2023财年实现净利润-1.75亿美元,同比增加3.85%
自选股智能写手 · 04-02
奥麦罗制药2023财年实现净利润-1.75亿美元,同比增加3.85%
Omeros 公司报告截至 12 月的季度业绩 - 收益摘要
Reuters · 04-02
Omeros 公司报告截至 12 月的季度业绩 - 收益摘要
Omeros Corp 预计每股亏损56美分 - 财报前瞻
Reuters · 03-30
Omeros Corp 预计每股亏损56美分 - 财报前瞻
奥麦罗制药盘中异动 早盘股价大跌5.04%
自选股智能写手 · 03-22
奥麦罗制药盘中异动 早盘股价大跌5.04%
公司概况
公司名称:
奥麦罗制药
所属市场:
NASDAQ
上市日期:
--
主营业务:
Omeros Corporation是一家临床阶段的生物制药公司,致力于发现、开发和商业化针对炎症、中枢神经系统凝血紊乱的产品。公司最先进的临床候选产品是来自其专利的PharmacoSurgeryTM平台,旨在提高接受过眼科、关节镜手术、泌尿科和其他外科手术的患者的临床疗效。公司的PharmacoSurgeryTM平台将低剂量组合的治疗药物直接输送到手术部位,可以抑制手术创伤引起的炎症和其他问题,提高手术后的临床效果。公司目前有四个正在发展的临床计划,包括三个来自pharmacosurgery平台的计划和一个从它形成的特许经营计划。此外,公司有一个临床程序管道和一个能够研究新的药物靶点的平台。公司保留每个候选产品和项目的所有制造,销售和分销的权利。
发行价格:
--
{"stockData":{"symbol":"OMER","market":"US","secType":"STK","nameCN":"奥麦罗制药","latestPrice":3.73,"timestamp":1714766400000,"preClose":3.72,"halted":0,"volume":158826,"hourTrading":{"tag":"盘后","latestPrice":3.8,"preClose":3.73,"latestTime":"18:56 EDT","volume":2879,"amount":10785.44,"timestamp":1714777019980},"delay":0,"floatShares":51711917,"shares":57944159,"eps":-1.87782,"marketStatus":"休市中","marketStatusCode":7,"change":0.01,"latestTime":"05-03 16:00:00 EDT","open":3.76,"high":3.84,"low":3.6101,"amount":588497.8825044,"amplitude":0.061801,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.87782,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714982400000},"adr":0,"listingDate":1254974400000,"adjPreClose":3.72,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":4,"preClose":3.72,"latestTime":"08:26 EDT","volume":5,"amount":20,"timestamp":1714739217423},"postHourTrading":{"tag":"盘后","latestPrice":3.8,"preClose":3.73,"latestTime":"18:56 EDT","volume":2879,"amount":10785.44,"timestamp":1714777019980},"volumeRatio":0.7387695636461648},"requestUrl":"/m/hq/s/OMER/wiki","defaultTab":"wiki","newsList":[{"id":"2432973274","title":"Omeros Corp 预计每股亏损58美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432973274","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432973274?lang=zh_cn&edition=full","pubTime":"2024-05-03 19:41","pubTimestamp":1714736509,"startTime":"0","endTime":"0","summary":" * Omeros Corp 预计在5月7日公布截至2024年3月31日的业绩时,季度收入将没有变化(预计) * * LSEG的分析师平均预计Omeros Corp每股亏损58美分。该公司在 2024 年 4 月 1 日发布的截至 3 月 31 日的每股收益指导介于 0.63 美元和 0.58 美元之间。* 华尔街对 Omeros Corp 的 12 个月目标价中值为 43.00 美元,高于其上一次收盘价 3.72 美元。5月3日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432827988","title":"奥麦罗制药盘中异动 股价大涨5.44%报3.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432827988","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432827988?lang=zh_cn&edition=full","pubTime":"2024-05-02 22:33","pubTimestamp":1714660427,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日22时33分,奥麦罗制药股票出现波动,股价大幅拉升5.44%。截至发稿,该股报3.59美元/股,成交量4.6389万股,换手率0.08%,振幅5.29%。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。奥麦罗制药股票所在的生物技术行业中,整体涨幅为0.31%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405022233477a57ed89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405022233477a57ed89&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432680664","title":"奥麦罗制药盘中异动 股价大涨5.08%报3.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432680664","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432680664?lang=zh_cn&edition=full","pubTime":"2024-05-02 02:10","pubTimestamp":1714587001,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日02时10分,奥麦罗制药股票出现异动,股价快速上涨5.08%。截至发稿,该股报3.31美元/股,成交量9.1821万股,换手率0.16%,振幅4.60%。奥麦罗制药股票所在的生物技术行业中,整体涨幅为1.19%。其相关个股中,Cytomx Therapeutics, Inc.、Cyclacel Pharmaceuticals, Inc.、Aptevo Therapeutics Inc.涨幅较大,Palisade Bio, Inc.、Cyclacel Pharmaceuticals, Inc.、Cytomx Therapeutics, Inc.较为活跃,换手率分别为1401.90%、851.96%、251.72%,振幅较大的相关个股有Cytomx Therapeutics, Inc.、Cyclacel Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ,振幅分别为188.34%、84.43%、77.43%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502021002861ea90a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502021002861ea90a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431784865","title":"奥麦罗制药盘中异动 早盘大幅拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431784865","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431784865?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:45","pubTimestamp":1714398302,"startTime":"0","endTime":"0","summary":"北京时间2024年04月29日21时45分,奥麦罗制药股票出现异动,股价大幅拉升5.08%。截至发稿,该股报3.31美元/股,成交量1.6588万股,换手率0.03%,振幅3.41%。奥麦罗制药股票所在的生物技术行业中,整体涨幅为0.85%。其相关个股中,Immunitybio, Inc.、Soleno Therapeutics, Inc.、Zyversa Therapeutics, Inc.涨幅较大,Zyversa Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Avenue Therapeutics, Inc.较为活跃,换手率分别为622.91%、27.73%、14.41%,振幅较大的相关个股有Cassava Sciences Inc C/Wts 15/11/2024、Immunitybio, Inc.、Eliem Therapeutics, Inc,振幅分别为33.33%、22.07%、18.59%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292145027a5729b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292145027a5729b8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429211524","title":"奥麦罗制药盘中异动 快速拉升5.19%报3.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429211524","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429211524?lang=zh_cn&edition=full","pubTime":"2024-04-23 22:17","pubTimestamp":1713881842,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日22时17分,奥麦罗制药股票出现异动,股价快速拉升5.19%。截至发稿,该股报3.24美元/股,成交量3.7837万股,换手率0.07%,振幅3.73%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体涨幅为1.15%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232217237922b2ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232217237922b2ca&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428660434","title":"奥麦罗制药盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428660434","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428660434?lang=zh_cn&edition=full","pubTime":"2024-04-20 02:12","pubTimestamp":1713550367,"startTime":"0","endTime":"0","summary":"北京时间2024年04月20日02时12分,奥麦罗制药股票出现波动,股价快速下跌5.30%。截至发稿,该股报3.04美元/股,成交量18.9274万股,换手率0.33%,振幅6.07%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体跌幅为0.12%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042002124787e822f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042002124787e822f8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427859818","title":"奥麦罗制药盘中异动 股价大跌5.19%报3.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427859818","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427859818?lang=zh_cn&edition=full","pubTime":"2024-04-16 00:23","pubTimestamp":1713198237,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日00时23分,奥麦罗制药股票出现波动,股价急速跳水5.19%。截至发稿,该股报3.57美元/股,成交量15.6878万股,换手率0.27%,振幅6.45%。奥麦罗制药股票所在的生物技术行业中,整体涨幅为0.41%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160023587a52e016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160023587a52e016&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427375440","title":"奥麦罗制药盘中异动 快速跳水5.33%报3.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427375440","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427375440?lang=zh_cn&edition=full","pubTime":"2024-04-13 03:05","pubTimestamp":1712948749,"startTime":"0","endTime":"0","summary":"北京时间2024年04月13日03时05分,奥麦罗制药股票出现异动,股价快速下挫5.33%。截至发稿,该股报3.73美元/股,成交量23.6553万股,换手率0.41%,振幅9.01%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体跌幅为1.60%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404130305497a527ba8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404130305497a527ba8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426674392","title":"奥麦罗制药盘中异动 急速拉升5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426674392","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426674392?lang=zh_cn&edition=full","pubTime":"2024-04-12 00:24","pubTimestamp":1712852669,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日00时24分,奥麦罗制药股票出现异动,股价大幅上涨5.48%。截至发稿,该股报3.84美元/股,成交量20.5528万股,换手率0.35%,振幅5.49%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体跌幅为0.63%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412002429791ff56a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412002429791ff56a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426446526","title":"奥麦罗制药盘中异动 下午盘股价大涨5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426446526","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426446526?lang=zh_cn&edition=full","pubTime":"2024-04-11 02:07","pubTimestamp":1712772463,"startTime":"0","endTime":"0","summary":"北京时间2024年04月11日02时07分,奥麦罗制药股票出现波动,股价快速上涨5.25%。截至发稿,该股报3.61美元/股,成交量29.0618万股,换手率0.50%,振幅8.69%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体跌幅为0.92%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240411020743791fb1bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240411020743791fb1bf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426639113","title":"奥麦罗制药盘中异动 早盘大幅拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426639113","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426639113?lang=zh_cn&edition=full","pubTime":"2024-04-09 22:23","pubTimestamp":1712672627,"startTime":"0","endTime":"0","summary":"北京时间2024年04月09日22时23分,奥麦罗制药股票出现波动,股价急速拉升5.02%。截至发稿,该股报3.59美元/股,成交量6.9816万股,换手率0.12%,振幅3.80%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体涨幅为0.21%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409222348791f6c89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409222348791f6c89&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425885990","title":"奥麦罗制药盘中异动 早盘股价大涨6.71%报3.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425885990","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425885990?lang=zh_cn&edition=full","pubTime":"2024-04-08 21:31","pubTimestamp":1712583099,"startTime":"0","endTime":"0","summary":"北京时间2024年04月08日21时31分,奥麦罗制药股票出现异动,股价急速上涨6.71%。截至发稿,该股报3.66美元/股,成交量1.5702万股,换手率0.03%,振幅0.00%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体跌幅为0.10%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404082131407a516629&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404082131407a516629&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425569694","title":"奥麦罗制药盘中异动 早盘股价大涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425569694","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425569694?lang=zh_cn&edition=full","pubTime":"2024-04-05 22:14","pubTimestamp":1712326456,"startTime":"0","endTime":"0","summary":"北京时间2024年04月05日22时14分,奥麦罗制药股票出现波动,股价大幅上涨5.13%。截至发稿,该股报3.28美元/股,成交量3.8476万股,换手率0.07%,振幅4.97%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体涨幅为0.85%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405221416861e38d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405221416861e38d9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424045764","title":"奥麦罗制药盘中异动 早盘快速下跌13.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424045764","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424045764?lang=zh_cn&edition=full","pubTime":"2024-04-02 21:31","pubTimestamp":1712064709,"startTime":"0","endTime":"0","summary":"北京时间2024年04月02日21时31分,奥麦罗制药股票出现波动,股价大幅跳水13.79%。截至发稿,该股报2.75美元/股,成交量9.2502万股,换手率0.15%,振幅5.64%。机构评级方面,在所有1家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体跌幅为1.14%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040221314987d59dd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040221314987d59dd5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424061820","title":"奥麦罗制药2023财年实现净利润-1.75亿美元,同比增加3.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424061820","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424061820?lang=zh_cn&edition=full","pubTime":"2024-04-02 16:11","pubTimestamp":1712045494,"startTime":"0","endTime":"0","summary":"12月31日,奥麦罗制药公布财报,公告显示公司2023财年净利润为-1.75亿美元,同比增加3.85%;其中营业收入为0.00美元,每股基本收益为-1.88美元。从资产负债表来看,奥麦罗制药总负债4.03亿美元,其中短期债务13.74百万美元,资产负债比为0.94,流动比率为0.05。机构评级:截至2023年12月31日,当前有1家机构对奥麦罗制药目标价做出预测,其中目标均价为13.00美元,其中最低目标价为13.00美元,最高目标价为13.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040216114487d46594&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040216114487d46594&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424774810","title":"Omeros 公司报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2424774810","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2424774810?lang=zh_cn&edition=full","pubTime":"2024-04-02 05:01","pubTimestamp":1712005310,"startTime":"0","endTime":"0","summary":" * Omeros Corp 公布的截至12月底的季度调整后每股亏损15美分,低于去年同期的每股收益2.05美元。两位分析师对该季度的平均预期是每股亏损 56 美分。* Omeros Corp公布的本季度每股收益为亏损15美分。* 公司当季亏损 907 万美元。* 本季度到目前为止,Omeros Corp 的股价保持稳定,今年到目前为止上涨了 5.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2423410946","title":"Omeros Corp 预计每股亏损56美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2423410946","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2423410946?lang=zh_cn&edition=full","pubTime":"2024-03-30 04:32","pubTimestamp":1711744336,"startTime":"0","endTime":"0","summary":" * Omeros Corp 将于4月1日发布截至2023年12月31日的财报,预计季度收入将保持不变。* * LSEG 的分析师平均预计 Omeros Corp 每股亏损 56 美分。* 目前分析师对该公司股票的平均评级为 \"买入\",建议的细分为 1 个 \"强烈买入 \"或 \"买入\",1 个 \"持有\",没有 \"卖出 \"或 \"强烈卖出\"。3月29日 - 本摘要于北京时间 3 月 29 日 20:32 机器生成。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421484817","title":"奥麦罗制药盘中异动 早盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421484817","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421484817?lang=zh_cn&edition=full","pubTime":"2024-03-22 22:22","pubTimestamp":1711117320,"startTime":"0","endTime":"0","summary":"北京时间2024年03月22日22时22分,奥麦罗制药股票出现波动,股价大幅下跌5.04%。截至发稿,该股报3.49美元/股,成交量6.8459万股,换手率0.11%,振幅3.81%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。奥麦罗制药股票所在的生物技术行业中,整体跌幅为0.02%。narsoplimab的临床开发目前主要集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032222220087e7b13c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032222220087e7b13c&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.omeros.com","stockEarnings":[{"period":"1week","weight":0.1841},{"period":"1month","weight":0.1841},{"period":"3month","weight":0.0971},{"period":"6month","weight":1.9141},{"period":"1year","weight":-0.2495},{"period":"ytd","weight":0.1407}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Omeros Corporation是一家临床阶段的生物制药公司,致力于发现、开发和商业化针对炎症、中枢神经系统凝血紊乱的产品。公司最先进的临床候选产品是来自其专利的PharmacoSurgeryTM平台,旨在提高接受过眼科、关节镜手术、泌尿科和其他外科手术的患者的临床疗效。公司的PharmacoSurgeryTM平台将低剂量组合的治疗药物直接输送到手术部位,可以抑制手术创伤引起的炎症和其他问题,提高手术后的临床效果。公司目前有四个正在发展的临床计划,包括三个来自pharmacosurgery平台的计划和一个从它形成的特许经营计划。此外,公司有一个临床程序管道和一个能够研究新的药物靶点的平台。公司保留每个候选产品和项目的所有制造,销售和分销的权利。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.015355},{"month":2,"riseRate":0.6,"avgChangeRate":0.064125},{"month":3,"riseRate":0.666667,"avgChangeRate":0.10543},{"month":4,"riseRate":0.4,"avgChangeRate":-0.026711},{"month":5,"riseRate":0.4,"avgChangeRate":0.011862},{"month":6,"riseRate":0.285714,"avgChangeRate":0.028538},{"month":7,"riseRate":0.357143,"avgChangeRate":0.030695},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.023197},{"month":9,"riseRate":0.357143,"avgChangeRate":0.003128},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.105593},{"month":11,"riseRate":0.6,"avgChangeRate":0.125441},{"month":12,"riseRate":0.533333,"avgChangeRate":0.031605}],"exchange":"NASDAQ","name":"奥麦罗制药","nameEN":"Omeros"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥麦罗制药(OMER)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥麦罗制药(OMER)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥麦罗制药,OMER,奥麦罗制药股票,奥麦罗制药股票老虎,奥麦罗制药股票老虎国际,奥麦罗制药行情,奥麦罗制药股票行情,奥麦罗制药股价,奥麦罗制药股市,奥麦罗制药股票价格,奥麦罗制药股票交易,奥麦罗制药股票购买,奥麦罗制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥麦罗制药(OMER)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥麦罗制药(OMER)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}